Embark Early Education Ltd
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 5.1K
- Market Cap
- $1.3B
- Website
- http://evotec.com
- Introduction
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
Global Exosome Market Size, Forecast, Trials and Trends
The Global Exosome Market: Size, Forecast, Trials, and Trends, 2024 report details the growing exosome market, highlighting advancements in diagnostics, therapeutics, and cosmetics. Exosomes, extracellular vesicles, are valuable for disease detection, diagnosis, and treatment. The market is expanding with 388 clinical trials underway, and first exosome therapeutics expected by 2029. Key players and technologies are profiled, along with market forecasts through 2030.
Global Oncology Based In Vivo (CRO) Market By Sources Analysis, Share, Trends, Size
The Global Oncology Based In Vivo (CRO) Market is projected to grow from USD 2.07 Billion in 2024 to USD 3.61 Billion by 2031, driven by increasing cancer prevalence, biotechnology advances, and R&D investments. Key challenges include high costs, model limitations, ethical considerations, and data standardization issues. North America leads the market, while Asia Pacific shows the fastest growth. Major players include Charles River Laboratory, ICON Plc, and Thermo Fisher Scientific.
Recursion announces positive phase 2 trial results for CCM drug
Recursion announced Phase 2 SYCAMORE trial results for REC-994, a CCM treatment, showing safety and promising MRI-based efficacy at the highest dose. The study, involving 62 participants, met primary safety endpoints but lacked significant patient-reported improvements. Recursion plans further FDA discussions and data publication. CCM affects 360,000 in the US and EU5, with Recursion leveraging its Recursion OS for drug development.
QUANTRO Therapeutics secures important Austrian research grant
QUANTRO Therapeutics GmbH secures an 18-month, EUR 1.7 million research grant from the Austrian Research Promotion Agency (FFG) to advance its transcriptomic discovery platform. This funding accelerates the platform's development to industrial level, enhancing multiplexing and automation for high-throughput screening of 'undruggable' transcription factor targets, revolutionizing drug discovery.
QUANTRO Therapeutics secures important Austrian research grant to advance transcriptomic discovery platform
QUANTRO Therapeutics GmbH received an 18-month, EUR 1.7 million research grant from the Austrian Research Promotion Agency (FFG) to advance its transcriptomic discovery platform. This funding will enhance the platform's throughput and multiplexing capabilities, enabling high-throughput screening for multiple drug targets simultaneously, including previously 'undruggable' ones, revolutionizing drug discovery.
QUANTRO Therapeutics Achieves Milestone with Boehringer Ingelheim in Cancer Treatment Research
QUANTRO Therapeutics achieved a milestone in its joint R&D with Boehringer Ingelheim, successfully applying QUANTROseq® technology to identify high-quality hits for undruggable transcription factors, aiming to develop first-in-class cancer treatments. The collaboration could exceed EUR 500 million in value, focusing on innovative cancer therapies.
QUANTRO Therapeutics reaches a milestone in developing first-in-class cancer treatments
QUANTRO Therapeutics achieved a milestone with Boehringer Ingelheim in developing first-in-class cancer treatments, successfully applying QUANTROseq® technology to identify high-quality hits for an undruggable transcription factor, aiming to transform cancer treatment options.
Quantro Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim
QUANTRO Therapeutics achieved a milestone in its joint R&D with Boehringer Ingelheim, successfully applying QUANTROseq® technology to identify high-quality hits for an undruggable transcription factor, advancing first-in-class cancer treatments. The collaboration aims to address unmet cancer treatment needs, with potential transaction value exceeding EUR 500 million.
QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim
QUANTRO Therapeutics announced a key milestone in its joint R&D program with Boehringer Ingelheim, successfully applying QUANTROseq® technology to achieve technical proof-of-concept and identify high-quality hits for an undruggable transcription factor, aiming to develop first-in-class cancer treatments. The collaboration could exceed EUR 500 million in value.
QUANTRO Therapeutics reaches a milestone in joint R&D with Boehringer Ingelheim
QUANTRO Therapeutics achieved a milestone in its joint R&D with Boehringer Ingelheim, successfully applying QUANTROseq® technology to identify high-quality hits for an undruggable transcription factor, advancing towards first-in-class cancer treatments. The collaboration aims to address unmet needs in cancer therapy, with potential transaction values exceeding EUR 500 million.
© Copyright 2025. All Rights Reserved by MedPath